Quarterly Result27 May 2026, 04:42 pm
Concord Drugs Approves FY26 Financial Results
AI Summary
Concord Drugs Ltd has announced its financial results for the quarter and year ending March 31, 2026. The Board of Directors approved the standalone and consolidated financial results during their meeting held on May 27, 2026. The results are available on the company's website and the BSE Limited website and will be published in newspapers as per SEBI regulations. Revenue from Operations increased to ₹7,873.68 lakhs in FY26 from ₹4,524.46 lakhs in FY25. Profit after tax stood at ₹105.50 lakhs in FY26 compared to ₹33.62 lakhs in FY25.
Key Highlights
- Concord Drugs approved financial results for the year ending March 31, 2026.
- The Board Meeting was held on May 27, 2026.
- Revenue from Operations increased to ₹7,873.68 lakhs in FY26.
- Profit after tax stood at ₹105.50 lakhs in FY26.
- Auditors Report issued by the Statutory Auditors was noted.
Price Impact
More from CONCORD
More in Quarterly Result